Ablation Therapy for Persistent Atrial Fibrillation

Authors

• Ikechukwu Ifedili, University of Tennessee Health Science Center
• Kristina Mouksian, Methodist Le Bonheur Healthcare
• David Jones, Methodist Le Bonheur Healthcare
• Ibrahim El Masri, University of Tennessee Health Science Center
• Mark Heckle, University of Tennessee Health Science Center
• John Jefferies, University of Tennessee Health Science Center
• Yehoshua C. Levine, University of Tennessee Health Science Center

Abstract

Atrial Fibrillation (AF) is the most common form of electrical disturbance of the heart and contributes to significant patient morbidity and mortality. With a better understanding of the mechanisms of atrial fibrillation and improvements in mapping and ablation technologies, ablation has become a preferred therapy for patients with symptomatic AF. Pulmonary Vein Isolation (PVI) is the cornerstone for AF ablation therapy, but particularly in patients with AF occurring for longer than 7 days (persistent AF), identifying clinically significant nonpulmonary vein targets and achieving durability of ablation lesions remains an important challenge.

Publication Title

Current Cardiology Reviews

Recommended Citation

Ifedili, I., Mouksian, K., Jones, D., El Masri, I., Heckle, M., Jefferies, J., & Levine, Y. (2022). Ablation Therapy for Persistent Atrial Fibrillation. Current Cardiology Reviews, 18 (2) https://doi.org/10.2174/1573403X17666210729101752